MedTrace Logo

Open-label Extension to Protocol 1042-0600

NCT00512317 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2023-01-17

Study results available
· View outcomes & findings →

Summary

To allow open-label extension to patients who have completed Protocol 1042-0600.

Conditions

  • Epilepsies, Partial

Interventions

DRUG

ganaxolone

liquid suspension dosed tid

Sponsors & Collaborators

  • Marinus Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-12-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512317 on ClinicalTrials.gov